Psychedelic and Hallucinogenic Drugs

On the Campaign Trail, Elon Musk Juggled Drugs and Family Drama

As Mr. Musk entered President Trump’s orbit, his private life grew increasingly tumultuous and his drug use was more intense than previously known.

By Kirsten Grind and Megan Twohey

Clinical Trials Drugs (Pharmaceuticals) Ethics and Official Misconduct Food and Drug Administration Institute for Clinical and Economic Review Lykos Therapeutics Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Psymposia Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

How an Activist Group Helped Torpedo MDMA Therapy

The fallout from the F.D.A.’s rejection of a new treatment for PTSD worries researchers and experts who fear other psychedelic drugs in the pipeline could be jeopardized.

By Andrew Jacobs and Rachel Nuwer

Cancer Cancer (Journal) Death and Dying Depression (Mental) Drugs (Pharmaceuticals) Food and Drug Administration Hospice Care Journal of Psychopharmacology Ketamine (Drug) Oregon Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Research Veterans Veterans Affairs Department

‘LIfe-Changing’ Psychedelic, for When Life Is Ending

People are turning to psilocybin, ketamine and other treatments for palliative care.

By Andrew Jacobs

Brain Entrepreneurship Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists

Can Psychedelics Help CEOs Boost Their Leadership Skills?

A growing cottage industry is dedicated to the theory that mind-altering drugs can improve business leadership.

By Todd Korol for The New York Times